McKesson news

Strong Q1 FY2027 results with 20% EPS growth, raised full-year guidance to 15-17% growth, broad-based revenue growth across segments, exceptional oncology performance (+33% revenue, +41% operating profit), and significant GLP-1 distribution tailwinds ($15B in Q1). Zacks Rank #3 (Hold) rating reflects balanced view despite headwinds.

Strong 10-year investment performance with 379.54% returns, outperforming S&P 500. Company demonstrates robust revenue growth (12% YoY), earnings growth (18% EPS increase), and strategic portfolio optimization through divestitures and acquisitions. Analysts have raised guidance and earnings estimates, with recent stock rally of 7.03% over four weeks. Growth drivers in high-margin specialty pharmaceuticals and oncology services are well-positioned for future expansion.

Major data breach affecting 284 million records with exposure of highly sensitive personal, medical, and financial information. This represents significant reputational damage, potential regulatory penalties, litigation risk, and loss of customer trust in the healthcare supply chain company.

Mentioned as one of three major U.S. wholesale distributors (along with Cardinal Health and Cencora) accounting for nearly all of AbbVie's domestic pharmaceutical sales; no specific sentiment expressed.

McKesson is mentioned as one of three major pharmaceutical distributors for AbbVie, representing a concentration risk. No independent analysis of McKesson is provided.

One of three major wholesalers accounting for 77% of Amgen's gross revenues, representing customer concentration risk.

Modest revenue growth of 7.7% year-over-year, EPS growth of 20.4% year-over-year, but carries same Zacks Rank #3 (Hold) rating as Cardinal Health with only 1.5% gain over the past month, suggesting in-line performance expectations.

Disclosed a data breach involving unauthorized access to third-party applications with alleged theft of data from Oncology & Multispecialty and Medical-Surgical business units.

Mentioned as a major pharmaceutical wholesaler/distributor for AbbVie products. No specific analysis provided regarding the company itself.

Mentioned as a competitor also expanding oncology and multispecialty platforms with a $2.25 billion acquisition of Precision Medicine Group. No specific performance data provided; serves as industry comparison point.

Generics portfolio remains a meaningful contributor to North American Pharmaceutical profitability with 5% prescription transaction volume growth. Operating profit grew 19% to $894 million, and ClarusONE generic sourcing program continues to create customer value.

Described as a 'hidden winner' and sector leader in pharmaceutical distribution with 193% dividend per share growth over 10 years, relatively smooth 15-year performance aside from one 50% drawdown (2015-2018), and positioned to benefit from rising healthcare spending trends.

Identified as major wholesale distributor partner for Eli Lilly's U.S. distribution, representing customer concentration risk but essential partnership for market access.

Highlighted as an established global player prioritizing technological innovation and comprehensive RCM solutions, positioned to capitalize on the growing market demand.

Listed as a key player in the rapidly growing healthcare analytics market

Listed among major companies in a rapidly expanding market segment, positioned to benefit from increased healthcare automation investments and bundled solution procurement trends.

McKesson's extensive pharmaceutical distribution network positions it to benefit from the expanding biopharmaceutical logistics market and increased demand for specialized supply chain solutions.

Company mentioned as a client of Evolve Executive Life Coaching. Mention is factual and indicates the company uses executive coaching services, but provides no information about company performance or outlook.